
MEDIA RELEASE

mylife™ OmniPod® from Ypsomed: the first insulin patch pump now available in Germany and the UK

Continuous and reliable insulin treatment finally available without tubing

Burgdorf, 15 July 2010 – From today, Ypsomed is launching the first insulin patch pump in Germany and the UK. The mylife™ OmniPod® is a continuous, tubing-free insulin infusion system. It offers people with diabetes who are dependent on insulin a high level of comfort and flexibility while at the same time opening up new possibilities in the treatment of toddlers and young people. The small, compact Pod is simply secured directly onto the skin with an adhesive, and it is easily controlled using the Personal Diabetes Manager (PDM), which also serves as a blood glucose meter. The mylife™ OmniPod® is available now nationwide in Germany and the UK via specialist diabetes practices. The costs will be reimbursed by health insurers.

Greater comfort and a better quality of life through the innovative insulin patch pump therapy

Simon Michel, Senior Vice President of Marketing & Sales at Ypsomed, is delighted: "With the mylife™ OmniPod® insulin patch pump, Ypsomed is the first provider to bring the very latest technology in insulin treatment to Europe, just six months after announcing the partnership with Insulet Corporation. We are pleased to enable people with diabetes to enjoy greater comfort and a better quality of life through our products." The mylife™ OmniPod® offers patients a greater degree of freedom and simplicity in use compared with conventional insulin pumps. Since the system does not require an infusion set tangled tubes are a thing of the past. With the mylife™ OmniPod®, the cannula is positioned automatically at the touch of a button. No needle visible for the patient. This automatic insertion provides a consistent placement of the cannula and reduces errors to a minimum. The alternative Pod placement options ensure greater flexibility and reduce stress on the skin and tissue. The Pod is adhesive, gentle on the skin, breathable and flexible. Unlike conventional infusion pumps the mylife™ OmniPod® is entirely patched on the skin. Due to the small size it is very discreet and not visible under clothing. The Pod can be used whilst swimming and during workouts without the need to detach the device. As an American study has shown, an interruption to the insulin supply lasting as little as 30 minutes has a considerable effect on the blood glucose level.¹

Advantages over intensified conventional therapy (ICT)

After switching to the mylife™ OmniPod®, ICT patients have improved long-term blood glucose levels (glycaemic control) through the continuous insulin supply without interruption, such as when the infusion set is uncoupled. This effect has been demonstrated in a study on the basis of an improved mean HbA1c (-0.49 percent).² The result is a reduced risk of possible secondary disease associated with diabetes. Furthermore, the bolus calculator integrated into the Personal Diabetes Manager (PDM) helps to determine the amount of insulin required. Since there is no longer any need for daily injections, patients are once more able to go about their daily lives with greater flexibility and less stress, which can be of benefit to the success of the therapy.

The OmniPod® insulin patch pump enjoys great success in the USA

Richard Fritschi, CEO of Ypsomed, is convinced of the success of the insulin patch pump in Europe: "The OmniPod® System has been available in the USA since 2006, and thousands of patients already enjoy the benefits of the OmniPod® insulin patch pump. An essential part of all new pump wearers in the USA choose the OmniPod® insulin patch pump over a conventional pump."

Mylife™ OmniPod® available now in Germany and the UK

The mylife™ OmniPod® is now available nationwide in Germany from specialist diabetes practices. Patients can obtain accessories from DiaExpert (www.diaexpert.de), a mail-order source for diabetes supplies, as well as from selected specialist diabetes care retailers. For further information, please visit www.mylife-diabetescare.de. In the UK, the mylife™ OmniPod® is available from Ypsomed Ltd. For further information, please visit www.mylife-diabetescare.co.uk.

For further information, please contact Daniel Kusio, Head of Investor & Public Relations at Ypsomed Holding AG, on tel. +41 34 424 41 43 or tel. +41 34 424 41 11. This media release as well as other documents are available in electronic form from www.ypsomed.com.



About the Ypsomed Group

The Ypsomed Group is a leading independent developer and manufacturer of injection systems for self-medication and a well-known diabetes specialist with more than 25 years' experience. The Ypsomed Group, which emerged in 2003 from the well-known Disetronic Group, offers insulin pumps, injection systems and pen needles for diabetes, growth hormone and infertility treatments as well as for other therapeutic purposes. Ypsomed is an innovation and technology leader with around 300 patent families and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. Ypsomed has established itself as a leading supplier of brand, co-branding and OEM products in both the retail trade and Business-to-Business sectors. As the partner of renowned pharmaceutical and biotech companies for many years, Ypsomed is particularly committed to advances in patient care. Under the mylife™ Diabetescare brand, Ypsomed offers patients products which it manufactures or distributes. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufacturing sites in Switzerland as well as leading independent diabetes product sales companies throughout Europe. The Ypsomed Group employs approximately 1200 employees.

¹ Zisser, Howard C., Quantifying the Impact of a Short-Interval Interruption of Insulin-Pump Infusion Sets on Glycemic Excursions, *Diabetes Care*, 2008 (31), 238-239.

² Kane M.P. et al., Clinical Experience with a Tubing-Free Insulin Pump System, *Infusystems USA*, 6. 2009 (1), 25-27.